{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:17:12Z","timestamp":1789820232171,"version":"4.0.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,14]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lung cancer, a significant global health challenge, notably the non-small-cell lung cancer (NSCLC) subtype, is a topic of utmost importance. The continuous advancements in NSCLC treatment, especially in the context of anaplastic lymphoma kinase (ALK)-positive NSCLC, are of great interest. A thorough review of alectinib\u2019s comparative efficacy and safety with other treatment modalities is a crucial step, and the role of clinicians and surgeons is integral in optimizing patient care. This review can also inform neoadjuvant therapies and enhance surgical education, facilitating more informed decision-making processes between surgeons and patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This comprehensive systematic review results from rigorous screening. Following a rigorous screening process of the PubMed, PubMed Central, and Medline databases by quality assessment and application of inclusion\/exclusion criteria filters, 9 relevant articles were identified that directly addressed the research question and provided a holistic understanding of it. The analysis included a total of 1403 patients from 9 different studies. Alectinib was given to 836 patients, while 567 patients received other chemotherapeutic drugs. The primary objective of this study was to evaluate and compare the efficacy of alectinib with other treatment modalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The analysis revealed that alectinib is promising for ALK-positive NSCLC cases, with significantly better efficacy and a positive impact on limiting central nervous system metastases. Alectinib\u2019s favorable safety profile, with medically manageable adverse events, provides reassurance about its safety compared with other treatment modalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Alectinib has emerged as a viable, significantly superior treatment option for patients with ALK-positive NSCLC. The superior efficacy and manageable safety profile are significant; it remains a novel therapy with much potential, such as neoadjuvant therapy, which will make significant strides in patient care of ALK-positive NSCLC. Therefore, it is crucial for healthcare professionals, including surgeons, to be well-versed in alectinib and its potential. This knowledge will empower them and instill confidence in their ability to provide the best care for their patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041506","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:01:12Z","timestamp":1739818872000},"page":"e41506","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: A systematic review"],"prefix":"10.1097","volume":"104","author":[{"given":"Monica","family":"Kharat","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"Nookala","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mamata Academy of Medical Sciences, Telangana, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabez David","family":"John","sequence":"additional","affiliation":[{"name":"Department of Medicine, Malla Reddy Institute of Medical Sciences, Telangana, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8099-238X","authenticated-orcid":false,"given":"Tirath","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Trinity Medical Sciences University School of Medicine, Ribishi, Saint Vincent and Grenadines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragnesh","family":"Kalyandrug","sequence":"additional","affiliation":[{"name":"Department of Medicine, Trinity Medical Sciences University School of Medicine, Ribishi, Saint Vincent and Grenadines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Department of Medicine, California Unit of Behavioral Science and Psychology, Fairfield, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaya","family":"Noor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv Jignesh Kumar","family":"Halani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Windsor University School of Medicine, Basseterre, St Kitts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Neurology, JFK University Medical Center, Edison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhilesh","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Medical Education, University of Texas Rio Grande Valley, Edinburg, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi","family":"Gadad","sequence":"additional","affiliation":[{"name":"Department of Medical Education, University of Texas Rio Grande Valley, Edinburg, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Millis","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, American University of Antigua, Antigua and Barbuda, Saint John."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250217","article-title":"Cancer. Who.int.","year":"2024"},{"key":"R2-20250217","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1513\/pats.200809-100TH","article-title":"Smoking and lung cancer: the role of inflammation.","volume":"5","author":"Walser","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"R5-20250217","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/cancers15030689","article-title":"Duration of immunotherapy in non-small cell lung cancer survivors: a lifelong commitment?","volume":"15","author":"Putzu","year":"2023","journal-title":"Cancers"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.21037\/tcr-22-1491","article-title":"State of the art and new perspectives in surgical treatment of lung cancer: a narrative review.","volume":"11","author":"Petrella","year":"2022","journal-title":"Transl Cancer Res"},{"key":"R8-20250217","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/OP.22.00475","article-title":"Stereotactic body radiotherapy for the management of early-stage non\u2013small-cell lung cancer: a clinical overview.","volume":"19","author":"Buchberger","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"R9-20250217","article-title":"Radiation therapy for lung cancer. Lung.org.","year":"2024"},{"key":"R10-20250217","article-title":"Non-small cell lung cancer chemotherapy.","year":"2024"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1200\/JCO.2016.70.5749","article-title":"Three-year follow-up of an alectinib phase I\/II study in ALK-positive non-small-cell lung cancer: AF-001JP.","volume":"35","author":"Tamura","year":"2017","journal-title":"J Clin Oncol"},{"key":"R12-20250217","article-title":"NSCLC targeted therapy.","year":"2024"},{"key":"R13-20250217","article-title":"FDA approves alectinib for ALK-positive lung cancer.","year":"2024"},{"key":"R14-20250217","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer.","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement positive non\u2013small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401).","volume":"12","author":"Iwama","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"100527","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer.","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg (London)"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"R19-20250217","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer.","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer.","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R21-20250217","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial.","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R22-20250217","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","article-title":"Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial.","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:01:16Z","timestamp":1739818876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041506","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}